Freenome, Inc. (FRNM) Stock

Healthcare · Diagnostics & Research · Member of Other US Stocks

Freenome, Inc. (FRNM) closed at USD 12.19 on 2026-10-14, a change of +13.9 % over the past year, with a market capitalization of USD 1.32B.

Freenome, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Freenome, Inc. key figures

Previous close

USD 12.19 (2026-10-14)

1-year change

+13.9 %

Market cap

USD 1.32B

Enterprise value

USD 2.89B

P/E ratio (trailing)

-6.17

P/E ratio (forward)

-5.12

EPS (trailing)

-1.99

EPS (forward)

-2.40

PEG ratio

n/a

Price to book

-0.23

Revenue growth

106.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.68

Employees

375

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Freenome, Inc.

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Freenome, Inc. and compare it with other stocks.